In this issue of the <em>JCI</em>, Hayashi and colleagues evaluated soluble forms of the immune checkpoint molecules PD-L1, PD-1, and CTLA-4 in the plasma of patients with advanced NSCLC who had been treated with anti-PD-1/L1 therapy. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.